4D Molecular Therapeutics to participate in panel discussions at Chardan's Genetic Medicines Conference on October 21, 2025.
Quiver AI Summary
4D Molecular Therapeutics, a late-stage biotechnology company, announced its participation in Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, where the management team will engage in panel discussions regarding in vivo gene therapies for ophthalmic and pulmonary indications. The company's lead product, 4D-150, is under Phase 3 development for wet age-related macular degeneration and aims to provide long-lasting treatment with a single injection. Additionally, their second product, 4D-710, is designed to deliver the CFTR gene for cystic fibrosis treatment via aerosol. Archived webcasts of the panels will be available on their website.
Potential Positives
- Management participation in a prominent genetic medicines conference enhances the company's visibility and establishes its thought leadership in the biotechnology field.
- The lead product candidate, 4D-150, is in Phase 3 development for treating wet age-related macular degeneration, demonstrating significant progress towards potential market introduction.
- 4D-710 represents a groundbreaking advancement in genetic medicine for cystic fibrosis, showcasing the company's innovative approach and potential impact on patient care.
- The webcasts of the conference will provide ongoing access to valuable information for investors and stakeholders, reflecting transparency and engagement with the community.
Potential Negatives
- None
FAQ
What is the purpose of 4DMT's participation in the conference?
4DMT's management will participate in panel discussions and one-on-one meetings to discuss advancements in genetic therapies.
When will 4DMT present at Chardan’s conference?
4DMT will present on October 21, 2025, with two panels scheduled at 9:30 a.m. ET and 2:00 p.m. ET.
How can I access the presentations from the conference?
Archived copies of the webcasts will be available for one year on the “Investors” section of the 4DMT website.
What are the main products developed by 4D Molecular Therapeutics?
4DMT's lead candidates include 4D-150 for retinal diseases and 4D-710 for cystic fibrosis.
Have 4DMT's products been approved by the FDA?
No, all of 4DMT's product candidates are still in clinical or preclinical development and not approved for marketing.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FDMT Insider Trading Activity
$FDMT insiders have traded $FDMT stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FDMT stock by insiders over the last 6 months:
- SCOTT BIZILY (Chief Legal Officer) sold 2,407 shares for an estimated $19,256
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FDMT Hedge Fund Activity
We have seen 59 institutional investors add shares of $FDMT stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REDMILE GROUP, LLC removed 885,067 shares (-88.8%) from their portfolio in Q2 2025, for an estimated $3,283,598
- MORGAN STANLEY removed 852,067 shares (-48.0%) from their portfolio in Q2 2025, for an estimated $3,161,168
- VR ADVISER, LLC removed 677,600 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,513,896
- BLACKROCK, INC. removed 536,397 shares (-11.8%) from their portfolio in Q2 2025, for an estimated $1,990,032
- NORGES BANK removed 446,604 shares (-89.2%) from their portfolio in Q2 2025, for an estimated $1,656,900
- FEDERATED HERMES, INC. added 417,157 shares (+33.4%) to their portfolio in Q2 2025, for an estimated $1,547,652
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND removed 412,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,528,520
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FDMT Analyst Ratings
Wall Street analysts have issued reports on $FDMT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Roth Capital issued a "Buy" rating on 08/12/2025
- Chardan Capital issued a "Buy" rating on 08/12/2025
- Goldman Sachs issued a "Buy" rating on 05/09/2025
- Barclays issued a "Overweight" rating on 05/09/2025
To track analyst ratings and price targets for $FDMT, check out Quiver Quantitative's $FDMT forecast page.
$FDMT Price Targets
Multiple analysts have issued price targets for $FDMT recently. We have seen 4 analysts offer price targets for $FDMT in the last 6 months, with a median target of $38.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $25.0 on 08/12/2025
- Salveen Richter from Roth Capital set a target price of $38.0 on 08/12/2025
- Salveen Richter from Goldman Sachs set a target price of $44.0 on 05/09/2025
- Gena Wang from Barclays set a target price of $38.0 on 05/09/2025
Full Release
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in panel discussions at Chardan’s 9 th Annual Genetic Medicines Conference on October 21 st , 2025. Members of the management team will also be available for one-on-one meetings.
Chardan’s 9
th
Annual Genetic Medicines Conference
| Panel Title: | In Vivo Gene Therapy: Breaking into Competitive Ophthalmic Indications |
| Presentation Time: | 9:30 a.m. ET |
| Webcast Link: | Webcast |
| Panel Title | In Vivo Gene Therapies in the Lung: Treating CF and Beyond |
| Presentation Time: | 2:00 p.m. ET |
| Webcast Link: | Webcast |
Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at
https://ir.4dmoleculartherapeutics.com/events
.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn .
Contacts:
Media:
Jenn Gordon
dna Communications
[email protected]
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]
